tbuckley/cabot-search huggingface dataset:
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
Authors: Ronen Arbel, Ruslan Sergienko, Michael Friger, Alon Peretz, Tanya Beckenstein, Shlomit Yaron, Doron Netzer, Ariel Hammerman
Journal: Nature Medicine (2022)
Prevention of pancreatic fluid collection recurrence after metal stent removal: plastic is not so fantastic!
Authors: Geoffroy Vanbiervliet
Journal: Endoscopy (2022)

Here is a debate that has been going on in therapeutic endoscopy rooms for many years: should plastic drainage stents be left in place after treatment of walled-of-necrosis (WON) and fluid collections? In the most recent large prospective study, disconnected pancreatic duct syndrome affected almost half of the patients (46.2 %) after acute necrotizing pancreatitis [1] and this has some bearing on treatment and outcome.
Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria in Patients With Idiopathic Inflammatory Myopathy and Anti–Melanoma Differentiation–Associated Protein 5 Positivity
Authors: Ho So, Jacqueline So, Tommy Tsz‐On Lam, Victor Tak‐Lung Wong, Roy Ho, Wai Ling Li, Chi Chiu Mok, Chak Sing Lau, Lai‐Shan Tam
Journal: Arthritis & Rheumatology (2022)

This study aimed to evaluate whether the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) could appropriately classify the diagnosis in adult patients with anti-melanoma differentiation-associated protein 5 (anti-MDA-5)-positive IIM. In addition, this study sought to determine whether a status of anti-MDA-5 positivity could be incorporated into the EULAR/ACR IIM classification criteria set and whether the recently modified criteria based on the presence of myositis-specific autoantibodies (MSAs) could be used to appropriately classify the diagnosis in patients with anti-MDA-5-positive IIM.Consecutive adult patients clinically diagnosed as having anti-MDA-5-positive IIM from 10 hospitals in Hong Kong were retrospectively recruited; patient characteristics were obtained from electronic medical records. We used a commercial line blot immunoassay to detect MSAs. We also determined a proposed set of phenotypic-serologic classification criteria specific for anti-MDA-5.In the patient cohort (n = 120; 31.7% with dermatomyositis, 68.3% with clinically amyopathic dermatomyositis [CADM]), the diagnosis could be classified with the EULAR/ACR criteria in 86 patients (71.7%) and with the Bohan and Peter criteria in 49 patients (40.8%). However, when combined with criteria specifically modified for CADM, the diagnosis could be classified by the Bohan and Peter criteria in 76.7% of patients. We observed that the sensitivity of the EULAR/ACR criteria could be improved to 98.3% if anti-MDA-5 antibody-positive status was considered as one of the criteria. The MSA-based criteria had 100% sensitivity. When we applied our proposed specific phenotypic-serologic criteria for the classification of patients with anti-MDA-5 antibodies, 97.5% of patients were able to be classified as having IIM.In this cohort of patients with anti-MDA-5-positive IIM, the diagnosis could not be classified by the EULAR/ACR criteria in almost 30% of patients. We suggest incorporating anti-MDA-5 antibody positivity as a criterion into existing criteria sets or developing specific criteria for patients with anti-MDA-5-positive IIM.
Wearable fitness tracker use in federally qualified health center patients: strategies to improve the health of all of us using digital health devices
Authors: Michelle Holko, Tamara R. Litwin, Fatima Munoz, Katrina I. Theisz, Linda Salgin, Nancy Piper Jenks, Beverly W. Holmes, Pamelia Watson-McGee, Eboni Winford, Yashoda Sharma
Journal: npj Digital Medicine (2022)

Abstract As the use of connected devices rises, an understanding of how digital health technologies can be used for equitable healthcare across diverse communities is needed. We surveyed 1007 adult patients at six Federally Qualified Health Centers regarding wearable fitness trackers. Findings indicate the majority interest in having fitness trackers. Barriers included cost and lack of information, revealing that broad digital health device adoption requires education, investment, and high-touch methods.
Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities
Authors: Fabrizio Piazza, Lutz Frölich, Alessandro Padovani
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018
Authors: Leticia M. Nogueira, Helmneh M. Sineshaw, Ahmedin Jemal, Craig E. Pollack, Jason A. Efstathiou, K. Robin Yabroff
Journal: JAMA Network Open (2022)

Black patients are less likely than White patients to receive guideline-concordant cancer care in the US. Proton beam therapy (PBT) is a potentially superior technology to photon radiotherapy for tumors with complex anatomy, tumors surrounded by sensitive tissues, and childhood cancers.To evaluate whether there are racial disparities in the receipt of PBT among Black and White individuals diagnosed with all PBT-eligible cancers in the US.This cross-sectional study evaluated Black and White individuals diagnosed with PBT-eligible cancers between January 1, 2004, and December 31, 2018, in the National Cancer Database, a nationwide hospital-based cancer registry that collects data on radiation treatment, even when it is received outside the reporting facility. American Society of Radiation Oncology model policies were used to classify patients into those for whom PBT is the recommended radiation therapy modality (group 1) and those for whom evidence of PBT efficacy is still under investigation (group 2). Propensity score matching was used to ensure comparability of Black and White patients' clinical characteristics and regional availability of PBT according to the National Academy of Medicine's definition of disparities. Data analysis was performed from October 4, 2021, to February 22, 2022.Patients' self-identified race was ascertained from medical records.The main outcome was receipt of PBT, with disparities in this therapy's use evaluated with logistic regression analysis.Of the 5 225 929 patients who were eligible to receive PBT and included in the study, 13.6% were Black, 86.4% were White, and 54.3% were female. The mean (SD) age at diagnosis was 63.2 (12.4) years. Black patients were less likely to be treated with PBT than their White counterparts (0.3% vs 0.5%; odds ratio [OR], 0.67; 95% CI, 0.64-0.71). Racial disparities were greater for group 1 cancers (0.4% vs 0.8%; OR, 0.49; 95% CI, 0.44-0.55) than group 2 cancers (0.3% vs 0.4%; OR, 0.75; 95% CI, 0.70-0.80). Racial disparities in PBT receipt among group 1 cancers increased over time (annual percent change = 0.09, P < .001) and were greatest in 2018, the most recent year of available data.In this cross-sectional study, Black patients were less likely to receive PBT than their White counterparts, and disparities were greatest for cancers for which PBT was the recommended radiation therapy modality. These findings suggest that efforts other than increasing the number of facilities that provide PBT will be needed to eliminate disparities.
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial
Authors: Olivier Mir, Marie Ferrua, Aude Fourcade, Delphine Mathivon, Adeline Duflot-Boukobza, Sarah Dumont, Eric Baudin, Suzette Delaloge, David Malka, Laurence Albiges, Patricia Pautier, Caroline Robert, David Planchard, Stéphane de Botton, Florian Scotté, François Lemare, May Abbas, Marilène Guillet, Vanessa Puglisi, Mario Di Palma, Etienne Minvielle
Journal: Nature Medicine (2022)
Salvage underwater endoscopic mucosal resection for recurrent gastric cancer after endoscopic submucosal dissection
Authors: Gentaro Tanabe, Shunsuke Yamamoto, Yoji Takeuchi, Eiji Mita
Journal: Endoscopy (2022)

Salvage endoscopic treatment of recurrent early gastric cancer (EGC) in scars after endoscopic submucosal dissection (ESD) is cumbersome. Conventional endoscopic mucosal resection (EMR) is usually difficult since submucosal fibrosis caused by previous treatments hinders the lifting of the lesion. ESD can be used as an alternative; however, it requires expertise. Underwater EMR was invented by Binmoeller et al. [1] and has been useful in treating recurrent colorectal polyps [2].
Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA
Authors: Tijn P J Jansen, Regina E Konst, Annemiek de Vos, Valeria Paradies, Steven Teerenstra, Stijn C H van den Oord, Aukelien Dimitriu-Leen, Angela H E M Maas, Pieter C Smits, Peter Damman, Niels van Royen, Suzette E Elias-Smale
Journal: JACC. Cardiovascular imaging (2022)
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
Authors: Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas-Socias, Sylvia F. Boj, Xavier Hernando-Momblona, Dominik Glodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink-Clements, Vanessa Zondag-van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fatrai, David Maussang, Jeroen J. Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nuciforo, Ramon Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan-Otto Attolini, Elena Sancho, Hector G. Palmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo S. Price, Robert G. J. Vries, Eduard Batlle, Mark Throsby
Journal: Nature Cancer (2022)
American Medical Jurisprudence and the Expert Witness
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tailoring micro/nano-fibers for biomedical applications
Authors: Bin Kong, Rui Liu, Jiahui Guo, Ling Lu, Qing Zhou, Yuanjin Zhao
Journal: Bioactive Materials (2022)

Nano/micro fibers have evoked much attention of scientists and have been researched as cutting edge and hotspot in the area of fiber science in recent years due to the rapid development of various advanced manufacturing technologies, and the appearance of fascinating and special functions and properties, such as the enhanced mechanical strength, high surface area to volume ratio and special functionalities shown in the surface, triggered by the nano or micro-scale dimensions. In addition, these outstanding and special characteristics of the nano/micro fibers impart fiber-based materials with wide applications, such as environmental engineering, electronic and biomedical fields. This review mainly focuses on the recent development in the various nano/micro fibers fabrication strategies and corresponding applications in the biomedical fields, including tissue engineering scaffolds, drug delivery, wound healing, and biosensors. Moreover, the challenges for the fabrications and applications and future perspectives are presented.
Endothelial-specific loss of Krüppel-Like Factor 4 triggers complement-mediated endothelial injury
Authors: Chelsea C. Estrada, Stephanie Cardona, Yiqing Guo, Monica P. Revelo, Vivette D. D’Agati, Siva Koganti, Jason Devaraj, John C. He, Peter S. Heeger, Sandeep K. Mallipattu
Journal: Kidney International (2022)
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink
Authors: Kayla E. Hanson, Kristin Goddard, Ned Lewis, Bruce Fireman, Tanya R. Myers, Nandini Bakshi, Eric Weintraub, James G. Donahue, Jennifer C. Nelson, Stan Xu, Jason M. Glanz, Joshua T. B. Williams, Jonathan D. Alpern, Nicola P. Klein
Journal: JAMA Network Open (2022)

Postauthorization monitoring of vaccines in a large population may detect rare adverse events not identified in clinical trials such as Guillain-Barré syndrome (GBS), which has a background rate of 1 to 2 per 100 000 person-years.To describe cases and incidence of GBS following COVID-19 vaccination and assess the risk of GBS after vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines.This cohort study used surveillance data from the Vaccine Safety Datalink at 8 participating integrated health care systems in the United States. There were 10 158 003 participants aged at least 12 years. Data analysis was performed from November 2021 to February 2022.Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccine, including mRNA vaccine doses 1 and 2, December 13, 2020, to November 13, 2021.GBS with symptom onset in the 1 to 84 days after vaccination, confirmed by medical record review and adjudication. Descriptive characteristics of confirmed cases, GBS incidence rates during postvaccination risk intervals after each type of vaccine compared with the background rate, rate ratios (RRs) comparing GBS incidence in the 1 to 21 vs 22 to 42 days postvaccination, and RRs directly comparing risk of GBS after Ad.26.COV2.S vs mRNA vaccination, using Poisson regression adjusted for age, sex, race and ethnicity, site, and calendar day.From December 13, 2020, through November 13, 2021, 15 120 073 doses of COVID-19 vaccines were administered to 7 894 989 individuals (mean [SE] age, 46.5 [0.02] years; 8 138 318 doses received [53.8%] by female individuals; 3 671 199 doses received [24.3%] by Hispanic or Latino individuals, 2 215 064 doses received [14.7%] by Asian individuals, 6 266 424 doses received [41.4%] by White individuals), including 483 053 Ad.26.COV2.S doses, 8 806 595 BNT162b2 doses, and 5 830 425 mRNA-1273 doses. Eleven cases of GBS after Ad.26.COV2.S were confirmed. The unadjusted incidence rate of GBS per 100 000 person-years in the 1 to 21 days after Ad.26.COV2.S was 32.4 (95% CI, 14.8-61.5), significantly higher than the background rate, and the adjusted RR in the 1 to 21 vs 22 to 42 days following Ad.26.COV2.S was 6.03 (95% CI, 0.79-147.79). Thirty-six cases of GBS after mRNA vaccines were confirmed. The unadjusted incidence rate per 100 000 person-years in the 1 to 21 days after mRNA vaccines was 1.3 (95% CI, 0.7-2.4) and the adjusted RR in the 1 to 21 vs 22 to 42 days following mRNA vaccines was 0.56 (95% CI, 0.21-1.48). In a head-to-head comparison of Ad.26.COV2.S vs mRNA vaccines, the adjusted RR was 20.56 (95% CI, 6.94-64.66).In this cohort study of COVID-19 vaccines, the incidence of GBS was elevated after receiving the Ad.26.COV2.S vaccine. Surveillance is ongoing.
Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study
Authors: N. Ezeh, K. Ardalan, K.A. Buhr, C. Nguyen, O. Al Ahmed, S.P. Ardoin, V. Barton, S. Bell, H. Brandling-Bennett, L. Castelo-Soccio, Y.E. Chiu, B.F. Chong, D.O. Co, I. Lara-Corrales, A. Cintosun, M.L. Curran, L.Z. Diaz, S.A. Elman, E. Fernandez Faith, M.T. Garcia-Romero, J. Grossman-Kranseler, M. Hogeling, A.D. Hudson, R.D. Hunt, E.M. Ibler, M.C. Marques, R.L. Monir, V. Oza, A.S. Paller, E. Putterman, P. Rodriguez-Salgado, J.J. Schoch, A. Truong, J. Wang, L. Wine Lee, R.A. Vleugels, M.S. Klein-Gitelman, E. von Scheven, V.P. Werth, Lisa.M. Arkin
Journal: Journal of the American Academy of Dermatology (2022)
Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study
Authors: Belen de Nicolas-Ruanes, Oscar M. Moreno-Arrones, David Saceda-Corralo, Angela Hermosa-Gelbard, Rita Rodrigues-Barata, Rocio Gil-Redondo, Emilio Garcia-Mouronte, Sergio Vañó-Galván
Journal: Journal of the American Academy of Dermatology (2022)
Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3·4 million individuals
Authors: Jianhua Wu, Ramesh Nadarajah, Yoko M. Nakao, Kazuhiro Nakao, Chris Wilkinson, Mamas A. Mamas, A. John Camm, Chris P. Gale
Journal: The Lancet Regional Health - Europe (2022)

Population-based studies of atrial fibrillation (AF) incidence are needed to inform health-service planning, but evidence is conflicting. We assessed trends of AF incidence in a large general population cohort from England.
Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease
Authors: Barbara Mara Klinkhammer, Simone Buchtler, Sonja Djudjaj, Nassim Bouteldja, Runolfur Palsson, Vidar Orn Edvardsson, Margret Thorsteinsdottir, Jürgen Floege, Matthias Mack, Peter Boor
Journal: Kidney International (2022)
Clinical management of metastatic colorectal cancer in the era of precision medicine
Authors: Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Josep Tabernero, Andres Cervantes
Journal: CA A Cancer Journal for Clinicians (2022)

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases. Appropriate clinical management of these patients is still a challenging medical issue. Major efforts have been made to unveil the molecular landscape of mCRC. This has resulted in the identification of several druggable tumor molecular targets with the aim of developing personalized treatments for each patient. This review summarizes the improvements in the clinical management of patients with mCRC in the emerging era of precision medicine. In fact, molecular stratification, on which the current treatment algorithm for mCRC is based, although it does not completely represent the complexity of this disease, has been the first significant step toward clinically informative genetic profiling for implementing more effective therapeutic approaches. This has resulted in a clinically relevant increase in mCRC disease control and patient survival. The next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine-based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC. CA Cancer J Clin. 2022;72:000-000.
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the international Sickle Cell World Assessment Survey
Authors: Ifeyinwa Osunkwo, John James, Fuad El‐Rassi, Alecia Nero, Caterina P. Minniti, Cassandra Trimnell, Jincy Paulose, Nicholas Ramscar, Tom Bailey, Olivera Rajkovic‐Hooley, Biree Andemariam
Journal: American Journal of Hematology (2022)

Abstract The international Sickle Cell World Assessment Survey (SWAY) reported a high impact of sickle cell disease (SCD) on patients' daily lives globally. In this study, we analyzed whether the reported burden differed between patients from the USA ( n = 384) and other high‐income (HI; n = 820) or low‐ to middle‐income (LMI; n = 941) countries. We assessed symptoms and complications, incidence/management of vaso‐occlusive crises (VOCs), treatment utilization/satisfaction, and the impact of SCD on education/employment. Certain symptoms (bone aches, insomnia, and joint stiffness) and complications (swollen/painful fingers/toes, gallstones, vision problems, blood clots, and asthma) were reported proportionally more by patients in the USA than in the HI/LMI countries. Self‐reported VOCs were more common (mean [SD]: 7.1 [5.7] vs. 5.5 [8.9] and 4.4 [4.6] in the previous 12 months) and were managed more often by hospitalization (52% vs. 24% and 32%) in the USA than the HI and LMI countries. A higher proportion of patients from the USA than the HI/LMI countries reported a negative impact of SCD on their employment/schooling. Although high overall satisfaction with current treatments was reported globally, most patients indicated a strong desire for alternative pain medications. There are likely several reasons for the relatively high patient‐reported burden in the USA group compared with the HI/LMI countries, including an older population and differences in newborn screening programs and pediatric/adult transition of care. It is clear that there is an urgent need for improved understanding and management of SCD globally, not just in the USA.
EEG monitoring after cardiac arrest
Authors: Claudio Sandroni, Tobias Cronberg, Jeannette Hofmeijer
Journal: Intensive Care Medicine (2022)

Hypoxic-ischaemic brain injury (HIBI) is the main cause of death and disability in patients who are comatose after return of spontaneous circulation (ROSC) from cardiac arrest [1].The electroencephalogram (EEG) is a useful tool to assess the severity of HIBI and provide prognostic information.In addition, EEG can be used to diagnose epileptiform activity in patients with suspected seizures and monitor the effectiveness of antiepileptic treatment.
Data Errors
Journal: JAMA (2022)

Katia Bruxvoort, PhD; Jeff Slezak, MS; Lei Qian, PhD; Lina S. Sy, MPH; Bradley Ackerson, MD; Kristi Reynolds, PhD; Runxin Huang, MS; Zendi Solano, BS; William Towner, MD; Cheryl Mercado, MPH; Steven J. Jacobsen, MD, PhD